Sfoglia per AUTORE
BALDESSARI C
Collezione AO Ordine Mauriziano

  

Items : 6

Prognostic Impact of IMDC Category Shift From Baseline to Nivolumab Initiation in Metastatic Renal Cell Carcinoma: A Sub-Analysis of the MEET-URO 15 Study. in Clinical genitourinary cancer / Clin Genitourin Cancer. 2025 Feb;23(1):102267. doi: 10.1016/j.clgc.2024.102267. Epub 2024 Nov 10.
2025
ASL Cuneo 2
AO Ordine Mauriziano

Puglisi S; Lipari H; Cavo A; Vignani F; Nolè F; Prati G; Morelli F; Spada M; Caffo O; Napoli MD; Atzori F; Malgeri A; Prati V; Sorarù M; Tudini M; Mollica V; Ricotta R; Baldessari C; Fratino L; Merler S; Procopio G; Naglieri E; Masini C; Zucali PA; Galli L; Sbrana A; Chiellino S; De Giorgi U; Maruzzo M; et alii...

2024
ASL Cuneo 2
AO Ordine Mauriziano

Roviello G; Lipari H; Cavo A; Vignani F; Nolè F; Prati G; Morelli F; Spada M; Caffo O; Di Napoli M; Atzori F; Malgeri A; Prati V; Sorarù M; Tudini M; Mollica V; Ricotta R; Baldessari C; Fratino L; Milella M; Procopio G; Naglieri E; Masini C; Zucali PA; Galli L; Chiellino S; Bimbatti D; De Giorgi U; Rebuzzi SE; et alii...

Post-progression outcomes of NSCLC patients with PD-L1 expression ? 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2021 May;148:24-35. doi: 10.1016/j.ejca.2021.02.005. Epub 2021 Mar 12.
2021
AO Ordine Mauriziano

Adamo V; Russo A; Metro G; De Filippis M; Simona C; Natalizio S; Migliorino MR; Landi L; Ricciardi S; Minuti G; Buti S; Nigro O; Cantini L; Russano M; Citarella F; Bracarda S; Zoratto F; Filetti M; Mansueto G; De Tursi M; Gori S; Rocco D; Chiari R; Rastelli F; Targato G; Gelibter A; Signorelli D; Mazzoni F; De Toma A; et alii...

Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study). in Therapeutic advances in medical oncology / Ther Adv Med Oncol. 2021 May 18;13:17588359211019642. doi: 10.1177/17588359211019642. eCollection 20
2021
AO Ordine Mauriziano

Bersanelli M; Casadei C; Pierantoni F; Roviello G; Cavo A; Vignani F; Nolè F; Prati G; Morelli F; Messina C; Messina M; Pignata S; Atzori F; Stellato M; Soto Parra HJ; Prati V; Santoni M; Cortellini A; Sorarù M; Mollica V; Panni S; Ricotta R; Baldessari C; Fratino L; Tomasello L; Merler S; Procopio G; Naglieri E; Masini C; et alii...

First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2020 May;130:155-167. doi: 10.1016/j.ejca.2020.02.023. Epub 2020 Mar 25.
2020
AO Ordine Mauriziano

Facchinetti F; Mazzaschi G; Barbieri F; Passiglia F; Mazzoni F; Berardi R; Proto C; Cecere FL; Pilotto S; Scotti V; Rossi S; Del Conte A; Vita E; Bennati C; Ardizzoni A; Cerea G; Migliorino MR; Sala E; Camerini A; Bearz A; De Carlo E; Zanelli F; Guaitoli G; Garassino MC; Ciccone LP; Sartori G; Toschi L; Dall'Olio FG; Landi L; et alii...

Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG. in Therapeutic advances in medical oncology / Ther Adv Med Oncol. 2020 Nov 2;12:1758835920968463. doi: 10.1177/1758835920968463. eCollection 2020.
2020
AO Ordine Mauriziano

Pignata S; De Giorgi U; Giannarelli D; Bersanelli M; Di Maio M; Verzoni E; Clemente A; Guadalupi V; Signorelli D; Tiseo M; Giusti R; Filetti M; Di Napoli M; Calvetti L; Cappetta A; Ermacora P; Zara D; Barbieri F; Baldessari C; Scotti V; Mazzoni F; Veccia A; Guglielmini PF; Maruzzo M; Rossi E; Grossi F; Casadei C; Cortellini A; Verderame F; et alii...